© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Aditxt, Inc. (ADTX) stock declined over -9.24%, trading at $0.51 on NASDAQ, down from the previous close of $0.56. The stock opened at $0.56, fluctuating between $0.50 and $0.56 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 20, 2026 | 0.56 | 0.56 | 0.50 | 0.51 | 159.91K |
| Feb 19, 2026 | 0.58 | 0.58 | 0.55 | 0.56 | 131.89K |
| Feb 18, 2026 | 0.61 | 0.62 | 0.59 | 0.59 | 99.29K |
| Feb 17, 2026 | 0.61 | 0.62 | 0.58 | 0.61 | 95.61K |
| Feb 13, 2026 | 0.69 | 0.69 | 0.60 | 0.62 | 192.99K |
| Feb 12, 2026 | 0.71 | 0.79 | 0.66 | 0.69 | 243.9K |
| Feb 11, 2026 | 0.73 | 0.73 | 0.67 | 0.69 | 103.89K |
| Feb 10, 2026 | 0.69 | 0.74 | 0.66 | 0.69 | 136.71K |
| Feb 09, 2026 | 0.65 | 0.80 | 0.65 | 0.70 | 334.14K |
| Feb 06, 2026 | 0.62 | 0.73 | 0.58 | 0.65 | 221.72K |
| Feb 05, 2026 | 0.66 | 0.67 | 0.62 | 0.62 | 92.44K |
| Feb 04, 2026 | 0.73 | 0.76 | 0.63 | 0.66 | 180.02K |
| Feb 03, 2026 | 0.77 | 0.83 | 0.70 | 0.72 | 104.83K |
| Feb 02, 2026 | 0.79 | 0.81 | 0.71 | 0.80 | 217.84K |
| Jan 30, 2026 | 0.81 | 0.84 | 0.78 | 0.82 | 138.57K |
| Jan 29, 2026 | 0.94 | 0.95 | 0.77 | 0.82 | 446.19K |
| Jan 28, 2026 | 0.98 | 1.02 | 0.87 | 0.92 | 195.22K |
| Jan 27, 2026 | 0.92 | 0.98 | 0.91 | 0.97 | 253.09K |
| Jan 26, 2026 | 1.03 | 1.11 | 0.81 | 0.91 | 753.71K |
| Jan 23, 2026 | 1.11 | 1.31 | 1.03 | 1.17 | 1.19M |
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Employees | 26 |
| Beta | 1.51 |
| Sales or Revenue | $645.18K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |